If you are:
Only When Necessary: INSUFFICIENT HUMAN DATA AVAIL; NONTERATOGENIC EFFECTS OBSERVED IN ANIMALS
Precaution: INSUFFICIENT DATA AVAIL; CONSIDER MATERNAL TREATMENT BENEFIT VS INFANT RISK
Absolute Contraindication: ANIMAL STUDIES SUGGEST EXCRETION OCCURS; POTENTIAL ADVERSE EFFECTS IN INFANT.
An adult over 60:
management or monitoring precaution: General-Not recommended as first line therapy in the elderly. Cardiovascular-Start at 2.5 mg/day and slowly titrate upward. Peripheral edema may be common. Lower drug clearance may result in increased sensitivity to blood pressure lowering effects. Gastrointestinal-May cause or worsen pre-existing constipation.
management or monitoring precaution: Musculoskeletal-Higher incidence of myopathy with age over 65. Hepatic-Monitor LFTs for liver dysfunction.
Giving Caduet to a child under 12:
management or monitoring precaution: Manufacturer recommends post-menarche females be counseled on appropriate contraception. Monitor for myopathy and liver dysfunction.
management or monitoring precaution: No safety and efficacy data for age < 6 years.
management or monitoring precaution: No established safety and efficacy in age <10 years and in pre-menarche girls.